MedTrace Logo

The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia

NCT02021201 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2020-03-26

No results posted yet for this study

Summary

This comparison is made between the effects of sertindole and risperidone on vulnerability indicators in schizophrenia. More specifically: the effects of these two antipsychotic compounds on basic processing of incoming information is studied. The investigators expect that the newer antipsychotic sertindole to be more effective in restoring information processing in schizophrenia patients than risperidone.

Conditions

Interventions

DRUG

risperidone

Patients with schizophrenia will be treated for 10 weeks treatment with risperidone

DRUG

Sertindole

Patients with schizophrenia will be treated for 10 weeks treatment with serindole

Sponsors & Collaborators

Principal Investigators

  • Birte Y Glenthoj, PhD · Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup

  • Bob Oranje, PhD · Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup

  • Birgitte Fagerlund, PhD · Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup

  • Rita S Godske, MD · Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02021201 on ClinicalTrials.gov